Equillium Q3 2024 Earnings Report
Key Takeaways
Equillium reported revenue of $12.2 million for the third quarter of 2024, compared to $8.9 million for the same period in 2023. Net loss for the quarter was approximately $7,000, or $(0.00) per basic and diluted share, compared to a net loss of $3.7 million, or $(0.11) per basic and diluted share, for the same period in 2023.
Retained rights to itolizumab following Ono partnership.
Positive interim analysis of Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease subjects.
Phase 2 ulcerative colitis study completed by partner Biocon.
Topline data from Phase 2 study in ulcerative colitis and Phase 3 EQUATOR study in aGVHD expected in Q1 2025.
Equillium
Equillium
Forward Guidance
Equillium believes that its cash, cash equivalents and short-term investments are sufficient to fund operations into the fourth quarter of 2025, assuming certain operational changes.